Lubiprostone preserves kidney function in chronic kidney disease by remodeling the gut microbiome

news-medical.net

The constipation drug lubiprostone showed potential in preserving kidney function in adults with moderate to severe chronic kidney disease. A phase 2 trial indicated lubiprostone improved creatinine-based kidney function over 24 weeks by reshaping the gut microbiome and enhancing mitochondrial health, not by reducing uremic toxins. Researchers suggest this mechanism could complement existing CKD treatments, potentially delaying disease progression.


With a significance score of 3.3, this news ranks in the top 11% of today's 26756 analyzed articles.

Get summaries of news with significance over 5.5 (usually ~10 stories per week). Read by 10,000+ subscribers: